Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Company

Abbott Laboratories

Tracked across 88 events · 1903 articles · First seen Feb 01, 2025 · Last active Sep 24, 2026

Sentiment
14
Attention
8
Events
88
Relationships
40
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
4 70
Regulatory
Impact: Abbott Laboratories, Inc. received 510(k) clearance from the United States — Food and Drug Administration for its Lipoprotein(a) Molarity Assay, which is a significant step forward for the company in cardiovascular risk assessment.
Jun 18, 2026 · 6 articles
4 70
Business
Impact: Abbott Laboratories Limited has begun commercial supplies under its Rs. 825 crore CDMO mandate, marking a significant milestone in its transition toward long-duration global manufacturing partnerships and strengthening its manufacturing infrastructure.
Jul 01, 2026 · 6 articles
2 50
Business
Impact: Abbott Laboratories acquired Carolina Liquid Chemistries Corporation, expanding its diagnostic capabilities and product offerings. This acquisition is expected to create synergies and benefit laboratories of all sizes.
Jun 01, 2026 · 7 articles
2 20
Business
Impact: Abbott Laboratories is celebrating 25 years of its listing on the New York Stock Exchange, reaffirming its commitment to global governance, transparency, and innovation, and highlighting its trusted presence in the US pharmaceutical market.
May 28, 2026 · 7 articles
1 20
Business
Impact: Palomino achieved a key milestone by listing its common stock on the OTCQB Venture Market, enhancing its public profile and enabling electronic settlement. This supports its commercialization roadmap and future exchange listing.
Jul 13, 2026 · 7 articles
4 -60
Business
Impact: Central company; reported 69% profit plunge, made Rs 240 crore provision, delayed semaglutide supplies, and faces securities investigation. Shares fell sharply.
Jul 09, 2026 · 23 articles
2 70
Business
Impact: Acquired Vega Links, expanding its market and technology portfolio; strengthened leadership and advisory board, positioning it as a leading AI interconnect company.
Aug 03, 2026 · 6 articles
2 20
Business
Impact: Neuland gains dedicated sterile API manufacturing capacity through Gland Pharma, supporting its growing demand and enhancing its CDMO capabilities. The corporate guarantee of ₹40 crore reflects its commitment.
Aug 05, 2026 · 6 articles
4 -20
Business
Impact: Abbott is the primary defendant, agreeing to pay $670 million to settle part of the NEC litigation. The settlement reduces legal uncertainty but does not resolve all claims, and the company continues to face thousands of lawsuits.
Aug 20, 2026 · 20 articles
4 80
Regulatory
Impact: Abbott is the developer and manufacturer of the Libre Duo 10 Day system, receiving FDA authorization for the world's first dual glucose-ketone sensor. This approval strengthens its diabetes care franchise and is expected to drive future revenue growth.
Aug 25, 2026 · 21 articles
4 -15
Regulatory
Abbott Laboratories agreed to pay approximately $385 million to resolve federal and state civil allegations that it sold contaminated powdered infant formula to government nutrition programs between January 2018 and December 2022. The United States…
Impact: Abbott is the central party, paying about $385 million to settle False Claims Act allegations over contaminated infant formula without admitting fault. The resolution removes legal uncertainty but keeps reputational and regulatory risk tied to its nutrition business.
Sep 14, 2026 · 6 articles
2 10
Business
Abbott Laboratories, Inc. (Nasdaq: IDXX) announced on Wednesday, September 16, 2026, that it has acquired CoVetAI Inc., a provider of AI-native ambient listening and clinical workflow software for veterinary practices. Financial terms of the transaction…
Impact: IDEXX is the acquirer, expanding its software and diagnostics ecosystem with CoVet's AI workflow tools. The deal is strategically positive but financially immaterial given undisclosed terms.
Sep 16, 2026 · 6 articles
2 -40
Regulatory
Pomerantz LLP is investigating claims on behalf of investors of Abbott Laboratories Limited regarding potential securities fraud or other unlawful business practices. The investigation stems from Dr. Reddy's announcement on July 22, 2026 of its…
Impact: Subject of the securities fraud investigation following disappointing Q1 FY2027 earnings and a significant provision for rejected semaglutide batches, which caused a 9.4% stock drop.
Aug 25, 2026 · 6 articles
2 25
Tech
Abbott Laboratories announced on September 15, 2026 that its Volt Pulsed Field Ablation System was used for the first time in Canada at the McGill University Health Centre in Montreal to treat patients with atrial…
Impact: Abbott Laboratories is the manufacturer of the Volt PFA System and the central entity of this event. The first Canadian use expands the commercial footprint of its electrophysiology portfolio and supports its competitive position in the PFA market.
Sep 15, 2026 · 6 articles
2 25
Business
Abbott Laboratories announced on September 17, 2026 a royalty-free, non-exclusive voluntary licensing agreement with Gilead Sciences covering investigational once-yearly lenacapavir for HIV prevention as pre-exposure prophylaxis (PrEP). The agreement is intended to support manufacturing readiness,…
Impact: Signed the royalty-free non-exclusive voluntary licence for once-yearly lenacapavir, expanding its HIV prevention portfolio and public-health access franchise across 120 licensed countries.
Sep 17, 2026 · 6 articles
3 25
Business
Abbott Laboratories and Takeda Pharmaceutical Company announced on September 18, 2026 an exclusive distribution agreement under which Dr. Reddy's will promote and distribute Takeda's dengue vaccine QDENGA across India's private market for pediatric and adult…
Impact: Exclusive private-market distributor of QDENGA in India, gaining a first-mover position in the country's first approved dengue vaccine and a potential new revenue stream from 2027.
Sep 18, 2026 · 20 articles
4 70
Business
Impact: Abbott Laboratories, a wholly owned subsidiary of Cosmos Health, will manufacture 2.86 million units of three pharmaceutical products for Pharmex S.A. over five years, leveraging its EU-GMP-licensed facility.
Jun 17, 2026 · 7 articles
4 70
Business
Impact: As a major player in the CLIA market, Abbott Laboratories is strengthening its market position through innovation and strategic collaborations, with its ARCHITECT and Alinity i systems playing a major role in advancing high-throughput immunodiagnostic testing globally.
Jun 05, 2026 · 6 articles
4 70
Business
Impact: Abbott is collaborating with Medtronic — Medtronic MiniMed to commercialize its dual glucose-ketone sensors, expanding its reach in diabetes technology and potentially increasing revenue from its medical device segment.
Jun 03, 2026 · 7 articles
2 40
Business
Impact: Abbott Laboratories S.A., a wholly owned subsidiary of Cosmos Health, acquired the international patent application and will lead the efforts in pursuing patent protection and expanding nanotechnology-based product development platforms.
Jun 08, 2026 · 8 articles
4 60
Regulatory
Impact: Abbott will exclusively commercialize SimpleScreen CRC, expanding its colorectal cancer screening portfolio alongside Cologuard, and leveraging its existing infrastructure.
Jul 27, 2026 · 6 articles
2 60
Business
Impact: As the parent company, Abbott Laboratories benefits from the subsidiary's strengthened CDMO capabilities and future revenue streams, though the financial impact is expected from 2028.
Aug 25, 2026 · 6 articles
2 30
Business
Impact: Abbott Laboratories, a wholly owned subsidiary of Cosmos Health>>>, manufactures C-Scrub Wash 4% and will be responsible for the production of the veterinary formulation, leveraging its existing infrastructure.
Jun 01, 2026 · 7 articles
1 55
Business
Impact: Key player; strong in in vitro diagnostics, the largest segment.
Jul 21, 2026 · 8 articles
1 55
Business
Impact: Key player; market growth supports its diagnostics portfolio.
Jul 08, 2026 · 6 articles
4 60
Tech
Impact: Abbott Laboratories, Inc. is identified as a top company in the epigenetics market, indicating its presence and potential to benefit from market growth.
Jun 26, 2026 · 6 articles
8 20
Accidents
Impact: Abbott Laboratories is a key partner in the urgent high-level coordination meeting convened by United States — Centers for Disease Control and Prevention, potentially involved in assessing medical countermeasures for the Ebola outbreak.
May 15, 2026 · 446 articles
4 50
Business
Impact: Abbott Laboratories is a manufacturing site owned by Cosmos Health, identified as a non-core real estate asset with a value of approximately $15 million that could be monetized.
Jun 04, 2026 · 6 articles
4 25
Tech
Impact: Its Lingo continuous glucose monitor is being integrated into Alphabet Inc. Health, potentially expanding its user base.
Aug 12, 2026 · 6 articles
4 0
Regulatory
Impact: The original acquisition that led to the arbitration; its sale to Daiichi is the root of the dispute.
Aug 31, 2026 · 11 articles
+ 58 more events View on Dashboard
50 Austin Scott filed lawsuit Abbott LaboratoriesAbbott $385M Baby Formula...
50 Kristine Cooper filed lawsuit Abbott LaboratoriesAbbott $385M Baby Formula...
50 Loren Cooper filed lawsuit Abbott LaboratoriesAbbott $385M Baby Formula...
Astec LifeSciences no relationship ↔ Abbott Laboratories Abbott Laboratories and Astec LifeSciences do not have a direct business-to-busi
Astec LifeSciences no relationship ↔ Abbott Laboratories Astec LifeSciences and Abbott Laboratories do not have a direct business-to-busi
Sun Pharma competitor ↔ Abbott Laboratories Abbott Laboratories competes directly with Sun Pharma in the global pharmaceutic
Sun Pharma competitor ↔ Abbott Laboratories Sun Pharmaceutical Industries acts as a major competitor to Abbott Laboratories
GenBioPro ↔ Abbott Laboratories
GenBioPro ↔ Abbott Laboratories
Kyle Duncan (judge) ↔ Abbott Laboratories
Kyle Duncan (judge) ↔ Abbott Laboratories
Cosmos Health ↔ Abbott Laboratories
Cosmos Health ↔ Abbott Laboratories
Liz Murrill ↔ Abbott Laboratories
Liz Murrill ↔ Abbott Laboratories
Greg Siokas ↔ Abbott Laboratories
Greg Siokas ↔ Abbott Laboratories
Stryker Corporation ↔ Abbott Laboratories
Stryker Corporation ↔ Abbott Laboratories
North American Cobalt Inc. ↔ Abbott Laboratories
North American Cobalt Inc. ↔ Abbott Laboratories
Joe Biden ↔ Abbott Laboratories
Joe Biden ↔ Abbott Laboratories
+ 10 more relationships View on Dashboard
ERGEN INTELLIGENCE
Track Abbott Laboratories live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.